247 related articles for article (PubMed ID: 9086342)
1. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for poor prognosis patients with urothelial tumors and effect of dose intensity.
Hibi H; Okamura K; Takashi M; Shimoji T; Miyake K
Hinyokika Kiyo; 1997 Feb; 43(2):89-96. PubMed ID: 9086342
[TBL] [Abstract][Full Text] [Related]
2. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
[TBL] [Abstract][Full Text] [Related]
3. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
Nakanishi S; Matsuzaki M; Morikawa H; Nakano M; Komatsu H
Hinyokika Kiyo; 2004 Oct; 50(10):667-71. PubMed ID: 15575216
[TBL] [Abstract][Full Text] [Related]
4. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
Kuroda M; Kotake T
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():362-9. PubMed ID: 7986116
[TBL] [Abstract][Full Text] [Related]
5. [Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma].
Narita S; Nakano M; Matsuzaki M; Watanabe J; Morikawa H; Murata H; Oda H; Komatsu H
Hinyokika Kiyo; 2005 Mar; 51(3):155-8. PubMed ID: 15852667
[TBL] [Abstract][Full Text] [Related]
6. Can patient selection for bladder preservation be based on response to chemotherapy?
Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
[TBL] [Abstract][Full Text] [Related]
7. [Current status of adjuvant chemotherapy of invasive bladder cancer].
Ozono S; Sasaki K; Watanabe S; Maruyama Y; Ohara S; Babaya K; Yamada K; Hirao Y; Okajima E
Hinyokika Kiyo; 1991 Dec; 37(12):1589-95. PubMed ID: 1785379
[TBL] [Abstract][Full Text] [Related]
8. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers].
Takenaka A; Gotoh A; Hara I; Gohji K; Ogawa T; Arakawa S; Matsumoto O; Kamidono S; Hamami G; Itani A
Gan To Kagaku Ryoho; 1990 Sep; 17(9):1909-15. PubMed ID: 2393308
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
10. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
Sella A; Flex D; Gafni D; Rabinovitz O; Sulkes A; Baniel J
Harefuah; 1999 Feb; 136(4):268-71, 340, 339. PubMed ID: 10914214
[TBL] [Abstract][Full Text] [Related]
11. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
13. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
Nishio Y; Shirahase T; Shichiri Y; Habuchi T; Matsuda T; Nishimura K; Hida S; Okada Y; Yoshida O
Hinyokika Kiyo; 1988 Aug; 34(8):1371-5. PubMed ID: 3195405
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer.
Yano M; Shiozaki H; Inoue M; Tamura S; Doki Y; Yasuda T; Fujiwara Y; Tsujinaka T; Monden M
World J Surg; 2002 Sep; 26(9):1155-9. PubMed ID: 12209246
[TBL] [Abstract][Full Text] [Related]
16. Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium.
Yamada Y; Itoh Y; Aoki S; Nakamura K; Taki T; Naruse K; Tobiume M; Zennami K; Katsuda R; Kato Y; Watanabe M; Nishikawa G; Minami M; Nakahira M; Ukai S; Sawada M; Kitamura A; Honda N
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1079-83. PubMed ID: 19277660
[TBL] [Abstract][Full Text] [Related]
17. Possible survival benefit of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin combination therapy (HD-MVAC) over conventional MVAC in metastatic urothelial carcinoma patients.
Inoue T; Obara T; Saito M; Kumazawa T; Yuasa T; Matuura S; Tsuchiya N; Satoh S; Habuchi T
Hinyokika Kiyo; 2007 Sep; 53(9):613-8. PubMed ID: 17933135
[TBL] [Abstract][Full Text] [Related]
18. [M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced renal pelvic and ureteral carcinoma].
Igawa M; Ueki T; Ueda M; Okada K; Usui T; Ohnishi Y; Kume T; Masu C; Ishino T; Nakatsu H
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2577-82. PubMed ID: 2673046
[TBL] [Abstract][Full Text] [Related]
19. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
Hong RL; Sheen TS; Ko JY; Hsu MM; Wang CC; Ting LL
Br J Cancer; 1999 Aug; 80(12):1962-7. PubMed ID: 10471046
[TBL] [Abstract][Full Text] [Related]
20. [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management].
Noguchi S; Kubota Y; Shuin T; Masuda M; Misaki H; Yao M; Kondoh K; Sakuramoto T; Hosaka M
Hinyokika Kiyo; 1994 Aug; 40(8):677-82. PubMed ID: 7942364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
